drugset / Trial / NCT02619097
Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objectives of the trial are to assess the safety and pharmacokinetics profile of pegolsihematide for treatment of anemia patient with myelodysplastic syndromes.
Timeline
- Start
- 2014-06
- Primary completion
- 2015-12
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegol-Sihematide | Unknown | 0.08 mg/kg | — |
| Subject | Pegol-Sihematide | Unknown | 0.2 mg/kg | — |
| Subject | Pegol-Sihematide | Unknown | 0.33 mg/kg | — |
| Subject | Pegol-Sihematide | Unknown | 0.5 mg/kg | — |
| Subject | Pegol-Sihematide | Unknown | 0.7 mg/kg | — |